截至2026年2月9日收盘，锦好医疗(920925)报收于22.73元，上涨0.71%，换手率2.27%，成交量1.26万 手，成交额2857.03万元。 业绩披露要点业绩快报 锦好医疗近日即将发布2025年年报，根据2月9日发布的业绩快报，归属净利润盈利0.152亿元，同比增 长153.62%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：2月9日主力资金净流入273.91万元，占总成交额9.59%。 来自业绩披露要点：锦好医疗预计2025年归属净利润盈利0.152亿元，同比增长153.62%。 当日关注点 交易信息汇总资金流向 2月9日主力资金净流入273.91万元，占总成交额9.59%；游资资金净流出5.11万元，占总成交额0.18%； 散户资金净流入34.64万元，占总成交额1.21%。 ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经讯，锦好医疗2月9日发布公告称，2025年，公司营业收入为3.08亿元，上年同期为1.86亿元，同比 上升65.26%。利润总额为1756万元，上年同期为475万元，同比上升270.03%。归属于上市公司股东的 净利润为1516万元，上年同期为598万元，同比上升153.62%。 （记者 曾健辉） ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年2月4日收盘，锦好医疗（920925）报收于22.7元，较前一交易日上涨0.09%，最新总市值为 22.35亿元。该股当日开盘22.75元，最高22.9元，最低22.62元，成交额达2551.43万元，换手率为 2.03%。 公司于近日披露《2025年限制性股票激励计划预留权益授予公告》。公告显示，惠州市锦好医疗科技股 份有限公司于2026年2月2日召开董事会，审议通过向3名激励对象授予20万股预留限制性股票，授予价 格为8.77元/股，股票来源为定向发行A股普通股。激励对象包括高级管理人员及核心员工，限售期分别 为12个月和24个月，分两期各解除限售50%。公司层面业绩考核目标为2026年营业收入不低于3.0亿元 或三年累计扣非净利润不低于5500万元，2027年营业收入不低于3.5亿元或三年累计扣非净利润不低于 9000万元。个人绩效考核达标方可解除限售。 最新公告列表 《关于惠州市锦好医疗科技股份有限公司2025 年限制性股票激励计划预留部分授予事项的法律意 见书》 ...

Core Viewpoint - The company, Jinhao Medical, is expected to see significant profit growth in 2025, driven by increased demand in the US OTC hearing aid market and strategic partnerships [1] Financial Performance - As of January 27, 2026, Jinhao Medical's stock closed at 23.75 yuan, down 3.46% from the previous trading day, with a total market capitalization of 2.338 billion yuan [1] - The company anticipates a net profit attributable to shareholders of 15 million to 16 million yuan for 2025, representing a growth of 150.98% to 167.72% compared to the previous year's profit of 597.65 million yuan [1] Business Strategy - The growth in performance is attributed to the rising demand in the US OTC hearing aid market, enhanced collaboration with brand partners, and the promotion of its own brand through a full-channel operation [1] - The acquisition of Intricon's hearing health business is expected to contribute approximately 20 million yuan in hearing aid chip sales revenue, an increase of about 16.5 million yuan year-on-year [1]

Core Viewpoint - The company expects a net profit attributable to shareholders of 15 million to 16 million yuan for the full year of 2025, driven by growth in the OTC hearing aid market and successful integration of acquired technology [1] Group 1: Performance Forecast - The company anticipates a year-on-year increase in net profit attributable to shareholders for 2025, primarily due to sustained demand in the U.S. OTC market and enhanced operational strategies [1] - The company has strengthened partnerships with key brand clients, leading to increased orders and revenue from brand partners [1] - The company has accelerated the development of its own brand channels, resulting in significant revenue growth from proprietary products [1] Group 2: Recent Financial Results - For the first three quarters of 2025, the company reported a main operating revenue of 196 million yuan, an increase of 82.44% year-on-year [2] - The net profit attributable to shareholders for the same period reached approximately 17.63 million yuan, reflecting a year-on-year increase of 565.54% [2] - The third quarter alone saw a main operating revenue of 82.22 million yuan, up 87.17% year-on-year, with a net profit of approximately 991.96 thousand yuan, marking a staggering increase of 1162.04% [2]

公司公告汇总 独立董事专门会议关于2025年限制性股票激励计划预留权益授予激励对象名单的审查意见及公示情况说 明的公告 截至2026年1月19日收盘，锦好医疗(920925)报收于24.79元，上涨0.08%，换手率2.99%，成交量1.65万 手，成交额4096.53万元。 当日关注点 交易信息汇总资金流向 1月19日主力资金净流出257.42万元，占总成交额6.28%；游资资金净流出285.54万元，占总成交额 6.97%；散户资金净流入11.55万元，占总成交额0.28%。 惠州市锦好医疗科技股份有限公司于2026年1月6日至1月16日对2025年限制性股票激励计划预留权益授 予的激励对象名单进行了内部公示，公示期间员工无异议。公司独立董事专门会议审查认为，激励对象 符合相关法律法规及《2025年限制性股票激励计划（草案）》规定的条件，具备任职资格，未发现不得 成为激励对象的情形。激励对象为公司及子公司的高级管理人员和核心员工，不包括独立董事及外籍员 工。独立董事认为本次激励对象的确定合法、有效。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号）， ...

《独立董事专门会议关于2025年限制性股票激励计划预留权益授予激励对象名单的审查意见及公 示情况说明的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 截至2026年1月19日收盘，锦好医疗（920925）报收于24.79元，较前一交易日上涨0.08%，最新总市值 为24.41亿元。该股当日开盘24.92元，最高24.92元，最低24.66元，成交额达4096.53万元，换手率为 2.99%。 公司近日发布公告称，惠州市锦好医疗科技股份有限公司于2026年1月6日至1月16日对2025年限制性股 票激励计划预留权益授予的激励对象名单进行了内部公示，公示期间员工无异议。公司独立董事专门会 议审查认为，激励对象符合相关法律法规及《2025年限制性股票激励计划（草案）》规定的条件，具备 任职资格，未发现不得成为激励对象的情形。激励对象为公司及子公司的高级管理人员和核心员工，不 包括独立董事及外籍员工。独立董事认为本次激励对象的确定合法、有效。 ...

Core Viewpoint - The company JinHao Medical has reported an increase in stock price and provided updates on the use of idle funds for purchasing financial products, indicating a strategic approach to asset management [1]. Group 1: Stock Performance - As of January 13, 2026, JinHao Medical's stock closed at 26.66 yuan, up 1.21% from the previous trading day [1]. - The stock opened at 26.6 yuan, reached a high of 27.5 yuan, and a low of 26.2 yuan, with a trading volume of 2.4 billion yuan and a turnover rate of 16.12% [1]. Group 2: Financial Product Investment - The company announced the use of up to 100 million yuan of idle self-owned funds to purchase low-risk, high-liquidity bank financial products, approved by the board on October 27, 2025 [1]. - As of January 13, 2026, the remaining balance of the purchased financial products was 60.2 million yuan, representing 16.92% of the company's audited net assets as of the end of 2024 [1]. - The company has added a purchase of 10 million yuan in structured deposits from the Bank of China, with a term of 119 days and an expected annual yield of 0.6% or 1.9%, funded by self-owned capital [1].

Group 1 - Jinhai Medical (920925) experienced a decline of 14.76% today, with a turnover rate of 32.59% and a transaction volume of 517 million yuan, showing a fluctuation of 14.83% [2][3] - The stock was listed on the daily turnover board due to its turnover rate reaching 32.59%, with a net selling amount of 158 million yuan from brokerage seats [3] - The top five brokerage seats accounted for a total transaction volume of 224 million yuan, with a buying amount of 33.13 million yuan and a selling amount of 191 million yuan, resulting in a net selling of 158 million yuan [3] Group 2 - The largest buying brokerage was Dongfang Caifu Securities, Lhasa Tuanjie Road First Securities, with a buying amount of 6.9757 million yuan, while the largest selling brokerage was Guotai Haitong Securities, Chongqing Jiefangbei, with a selling amount of 58.6743 million yuan [3] - Detailed trading information shows that multiple brokerage seats from Dongfang Caifu Securities were involved in buying, with significant amounts also sold by other brokerages [3]

最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《第三届董事会第十九次会议决议公告》 《2025年限制性股票激励计划预留权益授予的激励对象名单》 《广东东方昆仑(东莞)律师事务所关于惠州市锦好医疗科技股份有限公司2025年第四次临时股东 会法律意见书》 《2025年第四次临时股东会决议公告》 截至2026年1月7日收盘，锦好医疗（920925）报收于27.84元，较前一交易日下跌14.76%，最新总市值 为27.41亿元。该股当日开盘31.44元，最高31.44元，最低27.38元，成交额达5.17亿元，换手率为 32.59%。 近日，惠州市锦好医疗科技股份有限公司公布2025年限制性股票激励计划预留权益授予名单，共授予3 名激励对象200,000股限制性股票。其中，高级管理人员张亮获授100,000股，占比50.00%；袁金鹏获授 50,000股，占比25.00%；核心员工钟梅获授50,000股，占比25.00%。上述股份合计占公司总股本的 0.20%。 ...